MRD detection appears to offer robust prediction of relapse risk, particularly in the traditionally favourable core binding factor leukaemias and AML with NPM1 mutations in the absence of FLT3/ITD mutations 102, 103, 104, 105, and is being further tested and validated in intermediate‐ and poor‐risk AML both in the setting of post‐induction remission assessment as well as prior to and following aSCT. The gene discussed is FLT3; the disease is acute myeloid leukemia.